Latest Ratios: P/E Ratio -2.0x · EV/EBITDA N/A · ROE -71.5%. (2005–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $92M | $188M | $207M | $66M | $61M | $235M | $376M | $7M | $7M | $11M | $64M |
| Enterprise Value | $76M | $171M | $157M | $47M | $47M | $226M | $245M | $-1061307 | $-4043028 | $4M | $42M |
| P/E Ratio → | -1.96 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 155.65 | 316.73 | 302.78 | 135.50 | 158.13 | 653.40 | 1026.07 | 30.28 | 19.60 | 21.29 | 166.90 |
| P/B Ratio | 1.99 | 4.14 | 2.49 | 0.95 | 0.57 | 1.67 | 2.93 | 1.01 | 0.73 | 1.65 | 3.22 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 288.68 | 229.65 | 95.52 | 122.82 | 628.82 | 670.57 | -4.34 | -10.70 | 7.64 | 110.85 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -57.9% | -258.6% | -354.1% |
| Operating Margin | -8256.3% | -8256.3% | -7123.1% | -9305.7% | -10337.3% | -8037.6% | -5214.8% | -6817.8% | -4511.4% | -5068.5% | -10536.7% |
| Net Profit Margin | -7732.0% | -7732.0% | -6651.7% | -8492.0% | -10026.9% | -7880.5% | -5275.1% | -6709.7% | -4354.8% | -4932.1% | -10289.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -71.5% | -71.5% | -59.5% | -47.1% | -31.4% | -21.1% | -28.5% | -188.7% | -198.4% | -189.6% | -114.5% |
| ROA | -57.6% | -57.6% | -50.8% | -41.9% | -29.1% | -19.9% | -26.1% | -120.4% | -124.4% | -88.6% | -67.9% |
| ROIC | -118.9% | -118.9% | -87.7% | -47.7% | -26.7% | -33.4% | — | — | — | — | — |
| ROCE | -75.8% | -75.8% | -62.8% | -50.6% | -31.7% | -21.2% | -27.9% | -171.0% | -174.5% | -115.1% | -80.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | 0.24 | — | 0.20 | 0.84 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.37 | -0.60 | -0.28 | -0.13 | -0.06 | -1.02 | -1.16 | -1.14 | -1.06 | -1.08 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -9652.50 | — | -646.85 | -23.09 | -27.28 |
Net cash position: cash ($17M) exceeds total debt ($832000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.67 | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 | 21.79 | 2.37 | 4.31 | 2.40 | 5.00 |
| Quick Ratio | 3.67 | 3.67 | 7.08 | 7.41 | 14.25 | 22.28 | 21.79 | 2.37 | 4.31 | 2.40 | 5.00 |
| Cash Ratio | 3.56 | 3.56 | 6.83 | 7.17 | 13.48 | 21.47 | 21.41 | 2.13 | 3.86 | 2.08 | 4.86 |
| Asset Turnover | — | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.03 | 0.04 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 112.02 | 413.10 | 215.41 | 729.05 | 543.94 | 319.13 | 303.60 | 161.99 | 55.72 | 96.24 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | 0.7% | 0.0% | — | 100.0% | 100.0% | 100.0% | 38.1% |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.7% | 0.0% | 0.0% | 100.0% | 100.0% | 100.0% | 38.1% |
| Shares Outstanding | — | $67M | $48M | $45M | $44M | $39M | $21M | $6M | $2M | $481665 | $420568 |
Clinical trial funding insolvency
According to recent market data, CRDF trades at a price-to-sales ratio of 144.12, a figure that reflects extreme investor optimism regarding the potential of onvansertib rather than any underlying fundamental performance, as the company currently lacks the commercial revenue base to justify such a premium valuation multiple.
The elevated P/S ratio suggests that the market is pricing the company as a binary option on clinical success rather than a traditional operating business. Investors should monitor whether this valuation premium compresses as the cash runway shortens, as the current multiple appears disconnected from the reality of the company's pre-revenue status.
Based on reported financial statements, CRDF's ROIC has consistently remained in negative territory, reaching -34.7% in 2026Q1, which highlights the company's inability to generate positive returns on invested capital while it continues to aggressively burn cash to fund its ongoing clinical development programs.
The negative ROIC trend is a direct consequence of the company's high R&D expenditure relative to its negligible revenue. This pattern suggests that capital is being consumed at a rate that far outpaces the value creation potential of the current clinical pipeline, warranting caution regarding long-term shareholder value.
As indicated by the company's quarterly filings, the cash conversion cycle remains highly erratic, with DSO figures reaching as high as 486 days, suggesting that the firm's operational processes are not optimized for efficiency but are instead dictated by the irregular timing of clinical trial milestones and grant receipts.
The extreme volatility in DSO and DPO metrics reflects the lack of a recurring commercial business model. Analysts should interpret these figures as evidence of operational instability rather than standard working capital management, as the company lacks the scale to establish predictable payment or collection cycles.
Based on the 2026Q1 balance sheet, the current ratio of 3.27 appears superficially healthy, yet this metric masks the reality that the company's cash reserves are rapidly depleting to fund clinical trials, leaving the firm with limited flexibility to navigate potential delays in the regulatory approval process.
While the current ratio suggests an ability to cover short-term liabilities, the lack of recurring revenue means that liquidity is entirely dependent on the existing cash balance. Investors should monitor the burn rate closely, as the current liquidity position may prove insufficient to reach the next major clinical inflection point.
The most commonly misapplied metric for CRDF is the gross margin, which, at 100% in several periods, obscures the fact that the company has no commercial product and therefore no true cost of goods sold, rendering traditional profitability analysis entirely irrelevant for this stage of development.
Analysts should instead focus on the R&D-to-G&A expense ratio to evaluate management's capital allocation priorities. Relying on standard margin analysis for a pre-revenue biotech firm risks misinterpreting accounting artifacts as signs of operational strength, when in fact the business is entirely focused on speculative clinical development.
Includes 30+ ratios · 18 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CRDF stock.
Cardiff Oncology, Inc.'s current P/E ratio is -2.0x. This places it at the 50th percentile of its historical range.
Cardiff Oncology, Inc.'s return on equity (ROE) is -71.5%. The historical average is -94.1%.
Based on historical data, Cardiff Oncology, Inc. is trading at a P/E of -2.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Cardiff Oncology, Inc. has 100.0% gross margin and -8256.3% operating margin.